TABLE 1. Clinical and Procedural Characteristics of Study Patients
| Characteristic | Iopamidol-370 Group (n=204) | Iodixanol-320 Group (n=210) | P* |
|---|---|---|---|
| Data are presented as mean±SD where appropriate. | |||
| *t test for continuous variables; Fisher exact test for categorical variables. | |||
| Age, y | 72.4±9.0 | 70.5±9.9 | 0.04 |
| Gender, M/F | 138/66 | 127/83 | 0.15 |
| Body weight, kg | 82.7±17.7 | 86.7±20.6 | 0.03 |
| Body mass index, kg/m2 | 29.2±5.3 | 30.2±5.8 | 0.06 |
| Contrast volume, mL | 133.7±74.4 | 136.4±71.6 | 0.70 |
| Dose/body weight, gI/kg | 0.62±0.36 | 0.53±0.31 | 0.01 |
| Diabetes mellitus, n (%) | 78 (38.2) | 92 (43.8) | 0.27 |
| Time of postdose sampling, n (%) | |||
| 45 to 71 hours | 170 (83.3) | 175 (83.3) | 0.94 |
| 71 to 96 hours | 27 (13.2) | 29 (13.8) | |
| >96 hours | 7 (3.5) | 6 (2.9) | |
| Type of procedure, n (%) | |||
| Dx cardioangiography | 123 (60.3) | 128 (61.0) | 0.92 |
| PCI | 81 (39.7) | 82 (39.0) | |
| NAC premedication, n (%) | 79 (38.7) | 89 (42.4) | 0.48 |
| Intravenous volume supplementation/body weight (mL/kg) | 11.2±2.3 | 11.5±2.3 | 0.32 |
| Predose eGFR (mL/min per 1.73 m2), n (%) | |||
| 20 to 30 | 15 (7.4) | 17 (8.1) | 0.83 |
| 30 to 40 | 42 (20.6) | 40 (19.1) | |
| 40 to 50 | 82 (40.1) | 78 (37.1) | |
| 50 to 59 | 65 (31.9) | 75 (35.7) | |